Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02064439 · ClinicalTrials.gov registry record · Phase 3
Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
A Phase 3 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,365
- Enrollment target
NCT02064439 is a Phase 3 study that has completed, run by Bayer. The registered enrollment target is 3,365 participants.
The verdict
NCT02064439, a Phase 3 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,365 participants
- Enrollment target
Study Summary
This is a multicenter, randomized, double-blind, event-driven, superiority study for efficacy. Patients with confirmed symptomatic DVT (Deep Vein Thrombosis) or PE (Pulmonary embolism) who completed 6 or 12 months of treatment of anticoagulation are eligible for this trial
Interventions
- DRUG ASA
- DRUG BAY 59-7939
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,365 participants |
| Start Date | 2014-03-05 |
| Est. Completion | 2016-11-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02064439
The ClinicalTrials.gov registry entry for NCT02064439 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 3,365 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ASA is the first listed.
NCT02064439 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02064439 about?
NCT02064439 is a clinical study titled "Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)". This is a multicenter, randomized, double-blind, event-driven, superiority study for efficacy. Patients with confirmed symptomatic DVT (Deep Vein Thrombosis) or PE (Pulmonary embolism) who completed 6 or 12 months of treatment of anticoagulation are eligible for this trial
What is the current status of trial NCT02064439?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,365 participants. The study started on 2014-03-05. Estimated completion is 2016-11-04.
What interventions are being tested in trial NCT02064439?
The interventions under investigation include: ASA (DRUG), BAY 59-7939 (DRUG).
Who is sponsoring clinical trial NCT02064439?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.